Pharmaceuticals

Eylea Market Growth Patterns And Forecast Outlook Through 2030

April 30, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Expansion In Market Value Is Forecasted For The Eylea Market Between 2026 And 2030?

The eylea market has experienced robust expansion in recent years. It is anticipated to increase from $10.51 billion in 2025 to $11.15 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.2%. This historical growth can be attributed to several factors including the rising prevalence of age-related macular degeneration, an aging global population, the strong clinical efficacy of anti-vegf drugs, an expansion in ophthalmology specialty centers, and supportive reimbursement for retinal therapies.

The eylea market is projected for significant expansion in the coming years. This market is anticipated to reach $14.79 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.3%. Several factors contribute to this growth during the projection period, including an expanding diabetic demographic, wider application in other retinal conditions, advancements in long-acting formulations, enhanced drug delivery methods, and improved market access in developing regions. Key trends shaping the forecast period encompass extended-interval anti-VEGF treatments, a move towards the adoption of prefilled syringes, increased application in treating diabetic retinopathy, a rise in hospital-administered intravitreal procedures, and an emphasis on real-world data and patient outcomes.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9155&type=smp

What Key Drivers Are Fueling The Growth Of The Eylea Market?

The growing occurrence of ocular diseases is anticipated to boost the Eylea market. Ocular diseases are eye conditions that hinder the eye’s proper functioning, negatively impacting vision and clarity. These conditions frequently manifest without symptoms until they reach advanced stages. Eylea offers treatment for various ocular diseases, including wet age-related macular degeneration (AMD) and glaucoma, which cause damage to the retina or macula, consequently impairing vision. Eylea works by inhibiting the protein responsible for developing new, fragile blood vessels and by reducing retinal swelling resulting from blocked blood vessels. For instance, in 2024, data from the BrightFocus Foundation, a U.S.-based nonprofit organization dedicated to research on macular degeneration and glaucoma, indicates that around 80 million individuals worldwide are affected by glaucoma, a figure expected to increase to 111 million by 2040. Consequently, the rising incidence of ocular diseases is propelling the Eylea market.

What Segment Categories Shape The Eylea Market Segment Landscape?

The eylea market covered in this report is segmented –

1) By Product: Prefilled Syringe Package, Vial Package

2) By Disorder: Wet Age-Related Macular Degeneration (AMD), Diabetic Retinopathy, Other Disorders

3) By Application: Hospitals, Retail Pharmacy, Other Applications

Subsegments:

1) By Prefilled Syringe Package: Single-Dose Prefilled Syringes, Multi-Dose Prefilled Syringes

2) By Vial Package: Single-Dose Vials, Multi-Dose Vials

What Trends Are Influencing The Eylea Market?

Key entities active in the eylea market are concentrating on creating biologic drugs like aflibercept biosimilar to secure a competitive lead. An Aflibercept Biosimilar is a biologically comparable form of the original drug aflibercept, crafted to possess no clinically relevant distinctions and presenting an economical choice for managing specific ophthalmic ailments. For example, in September 2023, Biocon Biologics Ltd., an India-based biopharmaceutical firm, obtained marketing authorization from the European Commission (EC) for YESAFILI, an Aflibercept biosimilar, across the European Union (EU). This clearance was issued following a positive assessment from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) in July. YESAFILI is an ophthalmology product intended for addressing various eye conditions, and its approval confirms its similarity in terms of quality, safety, and efficacy to the reference product Eylea (aflibercept).

Who Are The Companies Operating Across The Eylea Market Value Chain?

Major companies operating in the eylea market are Regeneron Pharmaceuticals Inc., Bayer AG, Novartis AG, Roche Holding AG, Pfizer Inc., Amgen Inc., Sanofi S.A., AbbVie Inc., Alcon Inc., Genentech Inc., Johnson & Johnson, Samsung Bioepis Co. Ltd., Boehringer Ingelheim GmbH, Eisai Co. Ltd., Daiichi Sankyo Company Limited, Aerie Pharmaceuticals Inc., Otsuka Pharmaceutical Co. Ltd., Santen Pharmaceutical Co. Ltd., Allergan plc, BioMarin Pharmaceutical Inc.

Get The Full Eylea Market Report:

https://www.thebusinessresearchcompany.com/report/eylea-global-market-report

Which Region Has The Greatest Market Share In The Eylea Market?

North America was the largest region in the eylea market in 2025. Asia-Pacific is expected to be the fastest-growing region in the eylea market during the forecast period. The regions covered in the eylea market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Eylea Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/eylea-global-market-report

Browse Through More Reports Similar to the Global Eylea Market 2026, By The Business Research Company

Eylea Market Report 2026

https://www.thebusinessresearchcompany.com/report/eylea-global-market-report

Xylene Market Report 2026

https://www.thebusinessresearchcompany.com/report/xylene-global-market-report

Vanadium Market Report 2026

https://www.thebusinessresearchcompany.com/report/vanadium-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795